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Abstract
Background
There is still controversy as to whether initial combination treatment is superior to serial addi-
tion of anticholinergics after maintenance or induction of alpha blockers in benign prostatic
hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
Objective
The objective of this study was to determine the benefits and safety of initial combination
treatment of an alpha blocker with anticholinergic medication in BPH/LUTS through a sys-
tematic review and meta-analysis.
Methods
We conducted a meta-analysis of improvement in LUTS using International Prostate Symp-
tom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR),
and quality of life (QoL).
Results
In total, 16 studies were included in our analysis, with a total sample size of 3,548 subjects
(2,195 experimental subjects and 1,353 controls). The mean change in total IPSS improve-
ment from baseline in the combination group versus the alpha blocker monotherapy group
was -0.03 (95% CI: -0.14–0.08). The pooled overall SMD change of storage IPSS improve-
ment from baseline was -0.28 (95% CI: -0.40 - -0.17). The pooled overall SMD changes of
QoL, Qmax, and PVR were -0.29 (95% CI: -0.50 - -0.07), 0.00 (95% CI: -0.08–0.08), and
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0.56 (95% CI: 0.23–0.89), respectively. There was no significant difference in the number of
acute urinary retention (AUR) events or PVR.
Conclusions
Initial combination treatment of an alpha blocker with anticholinergic medication is effica-
cious for in BPH/ LUTS with improved measures such as storage symptoms and QoL with-
out causing significant deterioration of voiding function.
Introduction
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is a common
disease entity. It increases in prevalence according to age. Several medical treatments are avail-
able for BPH/LUTS. Alpha blockers are its first-line treatment because they are shown to be
effective and safe in relaxing prostatic urethra and bladder neck [1,2]. However, more than
half of BPH/LUTS patients have symptoms of overactive bladder (OAB) [3,4]. Although alpha
blockers have shown some efficacy, the effect of alpha blockers in the treatment of OAB still
remains uncertain [5,6]. Hence, BPH/LUTS patients with OAB or increased bladder sensation
could have persistent OAB symptoms despite using alpha blockers [7].
For the last few decades, treatment for OAB has been focused on prostate enlargement
itself. This has contributed to the onset of voiding symptoms and secondary OAB. Therefore,
treatment guidelines have been modified in order to focus more on the bothersome symptoms
themselves [2]. Moreover, OAB symptoms including urgency, frequency, nocturia, and urge
incontinence have been reported to be more bothersome than voiding symptoms. They result
in greater deterioration in quality of life [8,9].
To overcome the limitations in improving OAB symptoms with initial alpha blocker treat-
ment with more focus on the treatment of more bothersome symptoms, many clinicians have
considered the initial use of or earlier introduction of anti-muscarinic agents to control the
bothersome OAB symptoms [1,2]. However, initial or earlier treatment with anti-muscarinic
agents is controversial due to concerns over their safety. The major concern regarding the
safety of anti-muscarinic agents is their inhibitory effect on bladder detrusor contractility
which could result in a large amount of post-voided residual volume (PVR) and acute urinary
retention (AUR) [3,10–15]. To investigate the efficacy and safety of a combination treatment
of alpha blockers and anticholinergics, two systematic reviews (SRs) with meta-analyses have
been conducted to investigate the efficacy and safety of such combination treatment [5,6].
However, those two studies have two major limitations. First, their inclusion criteria for SRs
were expanded so that patients treated with “add on” anticholinergics after the initial or induc-
tion treatment with alpha blocker were included[6]. Second, many studies on initial combina-
tion treatment were not included[5].
Whether initial combination treatment is superior to serial addition of anticholinergics
after maintenance or induction of alpha blockers remains controversial. One recent study has
addressed this controversy with potent evidence. Matsukawa et al.[16] have reported that
alpha blocker monotherapy has limited effect on OAB, resulting in worse clinical outcomes
after 3 months even though the alpha blocker monotherapy is effective in the first 3 months.
They have also demonstrated the superiority of initial combinatorial therapy compared to
alpha blocker monotherapy for BPH patients with OAB [16].
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The aim of the current study was to determine the efficacy and safety of initial combination
of alpha blockers with anticholinergics for BPH patients with OAB using broad scientific
search methods to overcome the limitations encountered by previous SRs.
Materials and Methods
Inclusion criteria
A meta-analysis and systematic review were conducted according to predefined guidelines
provided by the Cochrane Collaboration. Both randomized controlled clinical trials (RCTs)
and non-RCTs were included in this analysis. Participants were patients who were diagnosed
with symptomatic BPH. Diagnostic tools included international prostate symptom score
(IPPS), storage symptoms of IPSS (storage IPSS), quality of life (QoL) score, maximum flow
rate (Qmax), post-void residual urine (PVR), and acute urinary retention (AUR).
Search strategies and inclusion of studies
Studies published before April 2016 April in MEDLINE were searched using MeSH headings
of prostatic hyperplasia for disease entity. For drugs used for prostatic hyperplasia, alpha
blockers (including tamsulosin, terazosin, doxazosin, alfuzocin, naftopidil, and silodosin) and
anticholinergics (including solifenacin, tolterodine, fesoterodine, propiverine, oxybutinin, tro-
pium sodium, and darifenacin) were searched within subheadings of studies. The detailed
search algorithm is shown below: "1. Prostatic Hyperplasia"[Mesh] 2. (Prostatic [tiab] OR
Prostate [tiab]) AND (Hyperplasia [tiab] OR Hypertrophy [tiab] OR Adenomas [tiab] OR
Adenoma [tiab]) OR "BPH" [tiab] 3. 1 OR 2 4. Solifenacin [Supplementary Concept] OR tol-
terodine [Supplementary Concept] OR fesoterodine [Supplementary Concept] OR oxybutynin
[Supplementary Concept] OR propiverine [Supplementary Concept] 5. Solifenacin [tiab] OR
tolterodine [tiab] OR fesoterodine [tiab] OR oxybutynin [tiab] OR propiverine [tiab] 6. 4 OR 5
7. tamsulosin [Supplementary Concept] OR silodosin [Supplementary Concept] OR Doxazo-
sin[Mesh] OR Terazosin [Supplementary Concept] OR alfuzosin [Supplementary Concept] 8.
Tamsulosin [tiab] OR silodosin [tiab] OR Doxazosin [tiab] OR Terazosin [tiab] OR alfuzosin
[tiab] 9. 7 OR 8 10. 6 OR 9 11. 10 AND 3 12. 11 AND (("randomized controlled trial"[Publica-
tion Type] OR "controlled clinical trial"[Publication Type] OR randomized [tiab] OR placebo
[tiab] OR "clinical trials as topic" [Mesh:noexp] OR randomly [tiab] OR trial [ti])) NOT ((ani-
mals [Mesh] NOT (humans [Mesh] AND animals [Mesh]))) 13. NOT "review" [Publication
Type] OR "review literature as topic" [MeSH Terms].”
Articles in EMBASE and the Cochrane Library were also searched. Searching strategies
included manual searching for additional studies published in English or other languages.
Studies were included if they met the following criteria: (i) Those with outcome measurements,
including at least one outcome among IPSS, QoL, Qmax, and PVR, (ii) interventions with ini-
tial combination treatment of alpha blockers and anticholinergic agents, (iii) disease entity of
prostatic hyperplasia, and (iv) RCTs.
Data collection and endpoints
Two investigators independently assessed the initial screening results obtained from electronic
databases. For non-English studies, native translator assisted the two independent investiga-
tors. Final inclusion of studies was based on discussion between the two investigators. After
determining the eligibility, data extraction was performed for baseline characteristics, includ-
ing source of country, race, number of patients, year, ages, inclusion criteria, and symptom
duration. The primary endpoints were outcomes, including efficacy, data of total IPSS, voiding
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IPSS, storage IPSS, Qmax, and QoL. The secondary outcome was safety, including PVR, inci-
dence of AUR, and other adverse events (AEs).
Methodological quality
Cochrane Collaboration tool was used to judge the methodological quality of included studies.
Meta-analysis of outcome findings and statistical analysis
To analyze continuous variables including total IPSS, storage IPSS, voiding IPSS, QoL, Qmax,
and PVR, standardized mean difference (SMD) and 95% confidence intervals (CIs) were cal-
culated. STATA version 14 software (Stata Corp LP, College Station, TX, USA) was used for all
data analysis. Meta-analyses were performed using the random-effect model of DerSimonian
and Laird to obtain pooled overall SMD with 95% CIs for outcomes.
Sensitivity analysis was performed to adjust for the effect of study quality because we
included double-blinded RCTs and single-blinded RCTs as well as unclear RCTs. Using sensi-
tivity analysis, the quality of studies were classified into subgroups by specific comparison of
means. Statistical heterogeneity was assessed using the I2 value and the Chi-squared test. A
p-value< 0.1 and an I2 value>50% were considered suggestive of significant statistical hetero-
geneity, prompting a random effects modeling estimate
Meta-regression analysis was conducted for each moderating factor. To examine potential
moderators (e.g., number of patients, study duration, country, and medication types),
restricted maximum likelihood (REML) was estimated for the variance of true effects.
Mann-Whitney U test was used for comparison between means (e.g., storage IPSS and
PVR). X2 test and Fisher’s exact test were used to compare proportions (e.g., AE) and fre-
quency variables between the combination group and the monotherapy group. A two-sided p-
value of 0.05 or less was considered as statistically significant.
Results
Inclusion of studies
The initial search identified a total of 1,851 articles from the electronic databases (Pubmed:
n = 466; Cochrane: n = 792; Embase: n = 514, and Koreamed: n = 89). After excluding 651
duplicated studies and 484 studies due to non-related topics, detailed evaluation was per-
formed. For the remaining 716 studies, a total of 671 studies were excluded due to ineligible
abstract or data. Among the remaining 51 eligible studies, thorough full-text evaluation were
performed. A total of 35 studies were excluded due to different study design including addi-
tional treatment with anticholinergics (n = 13), less than daily treatment with anticholinergics
(n = 2), incomplete data with wrong indications (n = 17), or duplicated data including post-
hoc analysis of previous RCTs (n = 3). Finally, 16 studies were selected for this present study
with a total of 23,716 subjects (2,304 experimental subjects and 1,412 controls). The detailed
process of filtering and inclusion is shown in Fig 1. Detailed characteristics of included studies
are described in Table 1.
Methodological quality
Quality assessment and characteristics of the 16 included studies are summarized in Table 2.
All studies utilized randomized methods and reasonable ITT analysis except one [17]. Eleven
studies [13,16,18–26] were conducted using allocation concealment with detailed description
of the concealment method. One study was a single-blinded study [18] while six studies were
Initial Combination Treatment of Alpha Blocker and Anticholinergics
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Fig 1. Search methods and inclusion criteria.
doi:10.1371/journal.pone.0169248.g001
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Table 1. General characteristics of included studies.
Study country Alpha
blockers
Anticholinergics Study
Duration
Age Subject Description Placebo
controlled
Storage
symptom
dominant
patient
Lee, 2005 Korea Doxazosin
4mg
Propiverine 20mg 8 weeks 50 OAB 6mo, BOO, AG (Abrams-
Griffith) score20, urgency1,
frequency8
No Yes
Kaplan, 2006 NA Tamsulosin
0.4mg
Tolterodine 4mg 12 weeks 40 IPSS12, QoL3, frequency8,
urgency3
Yes Yes
Maruyama,
2006
Japan Naftofidil
25–75mg
Propiverine 10–20mg
or Oxybutynin 2–6mg
12 weeks NA BPH, IPSS8, QoL2 No No
Yokoyama,
2009
Japan Naftofidil
50mg
Propiverine 20mg 4 weeks 50 LUTS/OAB, IPSS8, urinary
urgency1, frequency8, night-
time voiding frequency1,
PVR50ml
No Yes
Wu, 2009 China Tamsulosin
0.2mg
Tolterodine 2mg 12 weeks 50 BPH, IPSS8, QoL3, storage
subscore6, PVR<60ml,
Qmax15 ml/s, voided
volume200 ml
No Yes
Bae, 2011 Korea Alfuzocin
10mg
Propiverine 10mg 8 weeks 50 LUTS/BPH, IPSS12, IPSS
storage subscore4, PVR>200ml
No Yes
Gan, 2011 China Doxazocin
4mg
Tolterodine 4mg 12 weeks NA BPH, IPSS 13 No No
Shen, 2011 China Terazosin
2mg
Tolterodine 2mg 12 weeks 60 BPH, IPSS8, Qmax <15ml/s No No
Seo, 2011 Korea Tamsulosin
0.2mg
Solifenacin 5mg 12 weeks 40 LUTS/BPH/ED, IPSS total
score>12, QoL>3, IIEF-5 score
<20
No No
Lee, 2011 Korea Doxazosin
4mg
Tolterodine 4mg 12 weeks 50 LUTS/BPH/OAB, IPSS14,
voiding subscore8, storage
subscore 6, QoL3, micturition
frequency8, urgency1,20
cc, Qmax15 ml s, VV125 ml.
No Yes
Van
Kerrebroeck,
2013_S
17
European
countries
Tamsulosin
0.4mg
Solifenacin 3mg or
6mg or 9mg
12 weeks 45 LUTS, voiding and storage
symptoms, IPSS 13, Qmax 4–15
ml/s, VV120 ml
Yes No
Van
Kerrebroeck,
2013_N
13
countries
Tamsulosin
0.4mg
Solifenacin 6mg or
9mg
12 weeks 45 LUTS3mo, IPSS 13, Qmax
4–12 ml/s, VV120 m,
micturitions8
Yes No
Wang, 2013 China Doxazosin
4mg
Tolterodine 4mg 8weeks 50–
80
BPH/OAB, IPSS>8, OABSS>3,
QoL>3, PVR<100ml, Qmax>5ml/s
PSA<4ug/l
No Yes
Lee, 2014 Korea Tamsulosin
0.2mg
Solifenacin 5mg 12 weeks 40 LUTS/BPH/OAB, IPSS14,
voiding subscore8, storage
subscore6, QoL3, micturition
frequency8, urgency1, PV20
cc, Qmax15 ml/s, voided
volume125 ml.
No Yes
Lee, 2016 Korea Tamsolusin
0.2mg
Solifenacin 5mg 12 weeks 45 LUTS, IPSS8, OABSS3, PV
20mL
No Yes
Matsukawa,
2016
Japan Silodosin
8mg
Propiverine20mg 12 weeks 50 LUTS, IPSS8, QoL3,
OABSS3, urgency1, prostate
volume25ml, Qmax<15ml/s, V
V100ml, PVR<150ml
No Yes
OAB, overactive bladder; BOO, bladder outlet obstruction; IPSS, International Prostate Symptom Score; QoL, quality of life; BPH, benign prostatic
hyperplasia; LUTS, lower urinary tract symptom; VV, voided volume; PV, prostate volume; PVR, post-voided residual volume; Qmax, maximal urinary flow
rate; OABSS, overactive bladder symptom score.
doi:10.1371/journal.pone.0169248.t001
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Table 2. Methodological qualities of included studies.
Study Random
sequence
selection bias)
Allocation
concealment
(selection bias)
Blinding of
participants and
personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition bias)
Selective reporting
(reporting bias)
Other bias
Lee, 2005 Low risk
(Described
"randomized")
Low risk (All patients
who were eligible
based on voiding
diaries were
randomized to 1 of 2
treatment)
Low risk
(Described
"double-
blinding")
Low risk
(Described
"double-
blinding")
Low risk (Drop out
rate due to AE
(DOX 1/76,
Propiverine+ DOX
7/ 152), total drop
out (DOX 9/76,
Propiverine+DOX
21/152))
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved,
appropriate
declaration of
Helsinki)
Kalpan, 2006 Low risk
(Described
"randomized")
Low risk
(Randomized
1:1:1:1, The
randomization
scheme was
prepared by the
study biostatistician,
applying a block size
of 8, and produced)
by the randomization
administrator.
Patients were
dispensed study
medication and
randomized numbers
were taken from the
drug supply kit.
Low risk
(Described
"double-
blinding")
Low risk
(Described
"double-
blinding")
Low risk (Descirbed
"ITT", drop out rate
of each groups due
to AE (TAM 7/215,
Tol+TAM 20/225),
total drop out rate
(TAM 29/215,
Tolteradine+TAM
34/225))
High risk (Second
efficacy measures
Qmax is not
described,
Improvements in
maximum urinary
flow rate may be
less likely in patients
with greater urinary
flow rates at
baseline, reflecting
unilateral regression
to the mean artifact
and part of the
placebo effect
complex)
Low risk (IRB
approved)
Maruyama,
2006
Low risk
(Described
"randomized")
Low risk (Patients
were randomly
divided into two
groups based on
medical chart
numbers. Naftopidil
monotherapy was
administered to the
53 odd-numbered
patients
(monotherapy
group))
Unclear Unclear Low risk (Drop out
rate of each groups
due to AE
(monotherapy 1/45,
combine therapy 2/
41) was similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved)
Yokoyama,
2009
Unclear (Title
described
"randomized",
body described
"divided 3
groups")
Low risk (Subjects
were registered
through the study‘s
website and divided
according to daily
urinary urgency
episode)
High risk High risk Low risk (Drop out
rate due to AE 4/66,
did not make a
second visit 2/66,
couldn‘t be obtained
were excluded 2/66)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Unclear
Wu, 2009 Low risk
(Described
"randomized")
Unclear Unclear Unclear Unclear High risk Unclear
Bae, 2011 Low risk
(Described
"randomized")
Low risk
(Randomized 2:3,
The patients were
randomized by use of
a randomization
table)
Low risk (Single
blind)
High risk
(Single blind)
Low risk (No drop
out patients of each
groups due to AE)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved)
(Continued )
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Table 2. (Continued)
Study Random
sequence
selection bias)
Allocation
concealment
(selection bias)
Blinding of
participants and
personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition bias)
Selective reporting
(reporting bias)
Other bias
Gan, 2011 Low risk
(Described
"randomized")
Unclear Unclear Unclear Unclear Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Unclear
Shen, 2011 Low risk
(Described
"randomized")
Unclear Unclear Unclear Unclear High risk Unclear
Seo, 2011 Low risk
(Described
"randomized")
Low risk (Divided into
two groups by using
a table of random
sampling numbers)
Unclear Unclear Low risk (Drop out
of each groups
(TAM 1/30, TAM
+Soli 3/30) was
similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Unclear
Lee, 2011 Low risk
(Described
"randomized")
Low risk (The
randomization
scheme was prepare
d by the study
biostatistician,
applying a blocked
randomization to
minimize systematic
error and potential
investigator bias)
Low risk
(Described
"double-
blinding")
Low risk
(Described
"double-
blinding")
Low risk (Described
"ITT", drop out rate
of each groups due
to AE (DOX
+ placebo1/91,
DOX+Tol 3/85),
total drop out (DOX
+ placebo 28/91,
DOX+Tol 21/85)
was similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved)
Kerrebroeck,
2013_S
Low risk
(Described
"randomized")
Low risk
(Randomized
(1:1:1:1) using an
interactive response
technology to 12 wk
of double blind
treatment with
placebo)
Low risk
(Described
"double-
blinding")
Low risk
(Described
"double-
blinding")
Low risk (Drop out
rate of each groups
due to AE(placebo
3/341, TOCAS 5/
326, soli6+TAM 9/
337, soli9+TAM 8/
324) was similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk
(Appropriate
declaration of
Helsinki)
Kerrebroeck,
2013_N
Low risk
(Described
"randomized")
Low risk
(2:4:4:4:4:1:1:1
randomization ratio,
controlled absorption
system)
Low risk
(Described
"double-
blinding")
Low risk
(Described
"double-
blinding")
Low risk (Drop out
rate of each groups
due to AE (placebo
0/92, Soli3 1/43,
Soli6 1/43, Soli9 1/
44, Tocas0.4 5/179,
Tocas0.4+Soli3 5/
180, Tocas0.4
+Soli6 3/180,
Tocas0.4+Soli9 10/
176) was similar
rate)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk
(Appropriate
declaration of
Helsinki)
Wang, 2013 Low risk
(Described
"randomized")
Unclear Unclear Unclear Low risk (No drop
out patients of each
groups due to AE)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Unclear
(Continued )
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double-blinded[13,19–21,24,25]. The qualities of the included studies along with detailed rea-
sons for judgment of the qualities are described in Table 2.
Outcome findings
Detailed findings of efficacy in the included RCTs are shown in Fig 2. Total IPSS (15 trials),
storage IPSS (11 trials), QoL (11 trials), Qmax (12 trials), and PVR (11 trials) were analyzed.
Detailed data on total IPSS were reported in a total of 15 trials (n = 3,122; 1,978 experimen-
tal subjects and 1,144 controls). The pooled overall SMD change of IPSS improvement from
baseline for the combination group (experimental group) versus the alpha blocker monother-
apy group (control group) was -0.03 (95% CI: -0.14–0.08). There was significant (p = 0.002)
heterogeneity and Higgins’ I2 was 53.3% (Fig 2a). Although total IPSS did not show the signifi-
cant superior outcome in combination group, the direction was toward the superior outcome
for combination group.
Detailed data on storage IPSS were reported in a total of 11 trials (n = 2353; 1180 experi-
mental subjects and 1173 controls). The pooled overall SMD change of IPSS improvement
from baseline for the combination group versus the alpha blocker monotherapy group was
-0.28 (95% CI: -0.40–0.17). There was marginal significance (p = 0.077) in heterogeneity and
Higgins’ I2 was 38.5% (Fig 2b). To evaluate subjective factors for storage symptoms, subgroup
analysis was performed. Results showed that SMD changes in storage IPSS improvement from
baseline were -0.37 (95% CI: -0.51 - -0.23) in the storage-symptom dominant group and -0.14
(95% CI: -0.25 - -0.02) in the storage-symptom non-dominant group, respectively (Fig 2b).
Storage IPSS showed the significant superior outcome in combination group regardless of
storage dominant subgroup.
Table 2. (Continued)
Study Random
sequence
selection bias)
Allocation
concealment
(selection bias)
Blinding of
participants and
personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition bias)
Selective reporting
(reporting bias)
Other bias
Lee, 2014 Low risk
(Described
"randomized")
Low risk (The
randomization
scheme was
prepared by the
study biostatistician,
applying a blocked
randomization to
minimize systematic
error and potential
investigator bias)
Low risk (Blind to
patient)
Low risk
(Blinded to
investigators)
Low risk (Described
"ITT", drop out rate
of each groups due
to AE (TAM 1/80,
TAM0.2+Soli5 0/76)
was similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved)
Lee, 2016 Low risk
(Described
"randomized")
Unclear Unclear Unclear Low risk (Drop out
rate of each groups
due to AE (mono 6/
44, soli5mg 5/55,
soli 10mg 9/47) was
similar)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk (IRB
approved,
appropriate
declaration of
Helsinki)
Matsukawa,
2016
Low risk
(Described
"randomized")
Low risk (Using
random number
table)
Unclear Unclear Low risk (No drop
out patients of each
groups due to AE)
Low risk (The study
protocol had been
reported in the pre-
specified way
(primary and
secondary))
Low risk
(Appropriate
declaration of
Helsinki)
Kerrebroeck, 2013_S, SATURN trial; Kerrebroeck, 2013_N, NEPTUNE trial; DOX, doxazoxin; TAM, tamsulosin; IRB, Institutional Review Board
doi:10.1371/journal.pone.0169248.t002
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Fig 2. Forest plot diagram showing the effect of low-dose tamsulosin on total International Prostate
Symptom Score (IPSS) (a), storage IPSS (b), quality of life (QoL) (c), maximal urinary flow rate (Qmax)
(d), and post-voided residual volume (PVR) (e). Total IPSS and Qmax showed no significant improvement.
Storage IPSS and QoL showed significant improvement and PVR showed significant increase. The black
diamond signifies that the mean difference is in favor of IPSS. The size of each square depends on the weight
of each study. All data provided are for continuous outcomes.
doi:10.1371/journal.pone.0169248.g002
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Detailed data on QoL were reported in a total of 11 trials (n = 2,149; 1,085 experimental
subjects and 1,064 controls). The SMD change of QoL improvement from baseline for the
combination group versus the alpha blocker monotherapy group was -0.29 (95% CI: -0.50 -
-0.07). Heterogeneity test resulted in a value of p< 0.001. Higgins’ I2 value was 80.2% (Fig 2c).
Although the heterogeneity was high, QoL showed the significant superior outcome in combi-
nation group.
Detailed data on Qmax were reported in a total of 12 trials (n = 2,385; 1,243 experimental
subjects and 1,142 controls). The pooled overall SMD change of Qmax improvement from
baseline for the combination group versus the alpha blocker monotherapy group was -0.00
(95% CI: -0.08–0.08). A heterogeneity test resulted in a value of p = 0.766. Higgins’ I2 value
was 0% (Fig 2d). Qmax showed no significant superior outcome in combination group.
Detailed data on PVR were reported in a total of 11 trials (n = 2,079; 1,088 experimental
subjects and 991 controls). The SMD change of PVR improvement from baseline for the com-
bination group versus the alpha blocker monotherapy group was 0.56 (95% CI: 0.23–0.89). A
heterogeneity test resulted in a value of p< 0.001. Higgins’ I2 value was 91.7% (Fig 2e). To
determine selected factors for storage dominant symptoms, subgroup analysis was performed.
Results showed that SMD changes of PVR from baseline were 0.78 (95% CI: 0.09–1.48) in the
storage-symptom dominant group and 0.34 (95% CI: 0.18–0.49) in the storage-symptom non-
dominant group (Fig 2e). PVR showed significant increase in both group of storage dominant
subgroup.
Sensitivity analysis was performed to reveal the overall SMD change of storage IPSS and
PVR according to study quality in storage dominant groups. The combination of tamsulosin
and solifenacin produced studies of equally high quality compared to other combinations.
Hence, the quality of studies was replaced by drug combination type. Storage IPSS showed sig-
nificant improvement in both subgroups, but SMD was greater in tamsulosin and solifenacin
group (Fig 3a). PVR showed significant increase in combination groups. However, in both
subgroups, PVR showed a non-significant increase in the group of tamsulosin and solifencin,
with a value of 1.42 (95% CI, -0.41–3.24), and also in other types, with a value of 0.40 (95% CI,
-0.07–0.86) (Fig 3b).
Meta-regression analysis of IPSS storage and PVR showed that there was no significant
moderator effect for the number of patients, study duration, country, or particular combina-
tion therapy (Table 3).
Safety
Four of sixteen studies described adverse events beyond PVR and AUR. The incidence of
adverse events was higher in the combination group compared to that in the monotherapy
group (24.7% vs 19.3%, p = 0.001). Voiding difficulty, AUR, and significant PVR showed no
significant differences in incidence rates (p = 0.230, p = 0.325, and p = 1.000, respectively)
between the combination group and the monotherapy group. Among adverse events involving
the autonomic nervous system, constipation, dry mouth, and dyspepsia showed significant dif-
ferences (p< 0.001, p< 0.001, and p = 0.001, respectively), with the combination group having
higher incidence rates.
Publication bias
In the analysis performed for total IPSS, Begg and Mazumdar’s correlation was 0.10
(p = 0.922). Egger’s regression intercept was −0.002 (p = 0.998). Visual inspection of the
graphic in funnel plot (Fig 4) suggested that there was no evidence of publication bias or
small-study effect in this meta-analysis.
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Discussion
At the beginning of this study, our hypothesis was that storage symptoms were mainly bladder
problems, not originating from prostate issues. Hence, initial combination treatment with
alpha blockers and anticholinergics could be more effective without increasing the risk of
adverse events in BPH/LUTS patients with OAB symptoms.
Although voiding symptoms are the most common micturition symptoms among BPH/
LUTS patients and they can be well controlled by alpha blocker monotherapy, clinicians
should take into account that storage symptoms might not be well-controlled by alpha blocker
monotherapy [27]. More than 50% of BPH/LUTS patients have complaints of storage symp-
toms which are intolerable without using anticholinergics [12]. To overcome the limitative
Table 3. Meta-regression of storage IPSS and PVR.
Storage IPSS PVR
Variables k Coef.* SMD SE 95% CI P† k Coef.* SMD SE 95% CI P†
No. of patients 13 0.001 0.001 -0.002 0.005 0.332 15 0.007 0.006 -0.006 0.021 0.259
Study duration (weeks) 13 -0.005 0.041 -0.099 0.089 0.904 15 -0.059 0.120 -0.329 0.212 0.634
Country 0.520 0.164
Asian 11 -0.351 -0.492 -0.210 11 0.620 0.100 1.150
Western 2 -0.143 -0.256 -0.030 3 0.371 0.240 0.500
Combination agents 0.930 0.198
Tamsulosin plus Solifenacin 6 -0.266 -0.457 -0.075 7 0.360 0.010 0.720
Others 7 -0.317 -0.457 -0.176 7 0.560 0.230 0.890
doi:10.1371/journal.pone.0169248.t003
Fig 3. Sensitivity analysis for storage IPSS and PVR in the storage symptom dominant groups. Storage IPSS showed significant improvement
in both group, but SMD was greater in tamsulosin and solifenacin group. The size of each square depends on the weight of each study. All data
provided are for continuous outcomes.
doi:10.1371/journal.pone.0169248.g003
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effect of alpha blocker monotherapy, many studies have attempted to use anticholinergics ear-
lier in treatment with favorable efficacy and safety [3,10,12]. Clinical trials of “add on” thera-
pies of anticholinergics to conventional alpha blocker maintenance or induction treatment
with alpha blockers preceding clinical trials on the initial combination of the two medications
might have possible adverse effects caused by anticholinergics. They might have inhibitory
effect on contraction.
There are three main reasons that initial combination treatment is superior to “add on” or
induction treatment. First, adverse events including voiding difficulties, especially AUR, are
not as frequent as conventionally believed. Second, controlling storage symptoms themselves
is the most important factor in improving quality of life. Third, conventional alpha blocker
monotherapy has limited efficacy in improving storage symptoms, which can result in aggra-
vation of voiding symptoms after 3 months of treatment with alpha blocker monotherapy.
Safety is the first and the most important reason for recommending the initial use of anti-
cholinergics. A large-scale observational study has shown that anticholinergic medication is
not frequently recommended in clinical practice for the treatment of BPH/LUTS. Less than
3% of patients are given anticholinergics [28]. This low rate of usage of anticholinergics is
attributable to timidity amongst clinicians who believe that anticholinergic medications might
aggravate voiding symptoms by decreasing Qmax and increasing PVR, thus leading to urinary
Fig 4. Funnel plot with peusdo 95% confidence limits of total IPSS.
doi:10.1371/journal.pone.0169248.g004
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retention [29]. Liao et al. have reported that anticholinergic treatment is more effective in
patients with small prostate and storage dominant symptoms than in those who have large
prostate without storage dominant symptoms [30]. Recently, Lee et al [31] reported the effi-
cacy of initial combined treatment of tamsulosin plus solifenacin for men with LUTS. How-
ever, they also emphasized initial dose modification of anticholinergics due to to prevent
adverse events.
However, many emerging studies have reported that anticholinergics do not have abso-
lutely negative effect on detrusor contraction or increase AUR [3,32]. Two previous SRs with
meta-analyses have shown the safety of combination treatment, especially regarding the aggra-
vation of voiding symptoms and AUR. Similar results were obtained in the present study.5,6
Although there was a significant increase in PVR and a decreasing trend in Qmax in the initial
combination group, the incidence of AUR was exceedingly rare. This is the most consequential
finding of our SR.
The long-term safety of combination treatment has been proven by Matsukawa et al. [16].
Although combination treatment did increase PVR by a mean of 20 cc, only 13.7% of patients
in the combination group had increase of PVR of more than 50 cc. Moreover, more evidence
are emerging, showing that anticholinergic treatment is not significantly associated with a
safety issue even among patients with severe BOO (bladder outlet obstruction). Abrams et al.
have reported that treatment with tolterodine 2 mg for 3 months in BOO patients (confirmed
by urodynamic study) has produced no difference in the incidence of AUR compared to pla-
cebo treatment [33]. Kaplan et al. have reported that BOO patients with unfavorable outcomes
of previous alpha blocker monotherapy have favorable outcomes including improvement of
both Qmax and PVR when they are treated with tolterodine 4 mg for 6 months [34]. The main
reason for these positive results is that anticholinergics do not interfere with the releasing of a
large amount of acetylcholine during detrusor contraction [35].
Two recent SRs with meta-analyses and the results of the present study showed that other
adverse events such as dry mouth, constipation, and so on in addition to voiding difficulty
were not serious in the combination group.
The second important rationale for considering initial combination treatment is that it can
relieve storage symptoms. When treating LUTS in males, relief of storage symptoms have
historically played a key role in increasing patient satisfaction. Among storage symptoms,
urgency, urge incontinence, and nocturia are the main factors in patient satisfaction. Treat-
ment of these symptoms has resulted in an elevation of QoL [36,37]. The previous “add on”
study design in which anticholinergics are given after the initial alpha blocker treatment has
focused on the relief of bothersome storage symptoms. However, storage symptoms failed to
be relieved by alpha blocker monotherapy [3].
OAB has significant impact on QoL in both men and women. OAB has negative impact on
health-related QoL. It has been shown that increase levels of depression and sexual dysfunction
can negatively affect work productivity in EPIC sub-analysis studies [36,37]. In our study, QoL
showed a significant improvement in the combination treatment group compared to that in
the alpha blocker monotherapy group. Our results showed that, although total IPSS had a posi-
tive trend, storage IPSS showed significant improvement in both groups. This clarifies that
improvement of storage symptoms is the main factor that leads to improvement of QOL in
our results.
Although alpha blocker monotherapy can significantly improve micturition symptoms
within 3 months, it does not guarantee a persistent improvement in LUTS, especially in BPH/
LUTS patients with OAB. This factor is quite important, although many “add on” trials of anti-
cholinergics have demonstrated its efficacy. Besides those “add on” trials, long-term results of
comparisons between combination treatment and alpha blocker monotherapy have revealed
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that alpha blocker monotherapy is unable to offer long-term effect for BPH/LUTS patients
with OAB [16,32]. Moreover, in the group receiving alpha blocker monotherapy, the improve-
ment did not last longer than 3 months. In fact, it often aggravated the OAB after 3
months.16 On the contrary, with combination treatment, OAB symptoms could be resolved
within 4 weeks after starting the medications [16].
Two SRs with meta-analyses have described this issue. However, those studies need to be
updated. More initial combination trials have been conducted recently after the two SRs.
These studies need to be included in SRs. Moreover, the two previous SRs studies included
earlier combination studies in which anticholinergics were ‘added on’ after alpha blocker
induction. Therefore, they not true studies using the initial combination treatment strategy.
Our SR with meta-analysis is updated. It included most recent trials. Moreover, we not only
included double-blinded RCTs, but also included RCTs and non-RCTs to overcome the
issue of a small number of studies. We also tried to describe not only subjective outcomes
including IPSS, storage IPSS, voiding IPSS, and QoL, but also objective outcomes including
Qmax and PVR.
However, this study has several limitations. First, this study did not include urodynamic
finding (a gold standard for measuring voiding dysfunction) as an outcome measurement.
However, most studies on alpha blockers or anticholinergics did not include the results of uro-
dynamic studies. Their main focus was on subjective satisfactory outcomes such as IPSS. To
date, only a few studies have used urodynamic measurements to monitor clinical improvement
produced by anticholinergic treatment [33,38].
Second, this study did not include long-term outcomes. However, it is more important to
analyze the effect of initial combination treatment in the first 3 months because gradual
improvement of storage symptoms in BPH/LUTS patients with OAB has been found in the
long-term results of an initial combination trial [16]. Moreover, to date, only a few studies
have reported the outcomes after combination treatment at more than 3 months [32]. Third,
several trials have incomplete data. They could not be used in the analysis. For example, the
TIMES trial [13] is a very important and high-quality trial. However, it was not included in
our analysis because there was no measurement for the main outcomes. Addition or deletion
of outcome measurements in this study should not change the trend of the results of outcome
analysis.
Fourth, statistical heterogeneity was noted in our analysis. This was partially rectified
using random effects models [39]. Lastly, our study included heterogeneous drug combina-
tions. To overcome this phenomenon, sensitivity analysis was performed. It illustrated
favorable outcomes of tamsulosin and solifenacin combination treatment with low inner het-
erogeneity. This is attributable to the characteristics of clinical trials with the use of a combi-
nation of tamsulosin and solifenacin. Such trials were predominantly double-blinded RCTs.
We could not validate the superiority of this combination including tamuslosin and solifena-
cin compared with other combination types in this study, unlike that in the UK NHS trials
[40].
Conclusions
Initial administration of alpha blockers combined with anticholinergic agents provides favor-
able clinical outcomes with fewer adverse events as shown by both subjective and objective
outcome measurements. Such initial combination differs from earlier addition of anticholiner-
gics in that patients can benefit from earlier treatment results. OAB symptoms must be treated
directly with initial anticholinergic treatment to prevent the waste of treatment time associated
with alpha blocker monotherapy.
Initial Combination Treatment of Alpha Blocker and Anticholinergics
PLOS ONE | DOI:10.1371/journal.pone.0169248 January 10, 2017 15 / 18
Supporting Information
S1 Checklist. PRISMA Check List.
(DOC)
Acknowledgments
This study was supported by Astellas Pharma Korea, Inc. and Soonchunhyang University
Research Fund, Republic of Korea. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
Conceptualization: JHK.
Data curation: HYS HC SWD.
Formal analysis: HJK YMK.
Funding acquisition: JHK.
Investigation: JHK HJK.
Methodology: JHK HJK YMK.
Project administration: JHK.
Resources: HYS.
Software: JHK HYS.
Supervision: JYP WJY JHB YSS.
Validation: JHK HJK YMK.
Visualization: JHK HYS.
Writing – original draft: JHK.
Writing – review & editing: JHK.
References
1. Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, et al. (2011) Outline of JUA clinical guide-
lines for benign prostatic hyperplasia. Int J Urol 18: 741–756. doi: 10.1111/j.1442-2042.2011.02860.x
PMID: 22050351
2. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al. (2013) EAU guidelines on the
treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic
obstruction. Eur Urol 64: 118–140. doi: 10.1016/j.eururo.2013.03.004 PMID: 23541338
3. Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, et al. (2011) Solifenacin as add-on ther-
apy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, ran-
domized controlled study. Urology 78: 126–133. doi: 10.1016/j.urology.2011.02.055 PMID: 21601248
4. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, et al. (2009) Clinical guidelines for
overactive bladder. Int J Urol 16: 126–142. doi: 10.1111/j.1442-2042.2008.02177.x PMID: 19228224
5. Filson CP, Hollingsworth JM, Clemens JQ, Wei JT (2013) The efficacy and safety of combined therapy
with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J
Urol 190: 2153–2160. doi: 10.1016/j.juro.2013.05.058 PMID: 23727412
6. Hao N, Tian Y, Liu W, Wazir R, Wang J, et al. (2014) Antimuscarinics and alpha-blockers or alpha-
blockers monotherapy on lower urinary tract symptoms—a meta-analysis. Urology 83: 556–562. doi:
10.1016/j.urology.2013.10.034 PMID: 24361007
Initial Combination Treatment of Alpha Blocker and Anticholinergics
PLOS ONE | DOI:10.1371/journal.pone.0169248 January 10, 2017 16 / 18
7. Matsukawa Y, Hattori R, Sassa N, Yamamoto T, Gotoh M (2013) What are the factors contributing to
failure in improvement of subjective symptoms following silodosin administration in patients with benign
prostatic hyperplasia? Investigation using a pressure-flow study. Neurourol Urodyn 32: 266–270. doi:
10.1002/nau.22286 PMID: 22907775
8. Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J (2006) Impact on quality of life of different
lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol
Nephrol 40: 485–494. doi: 10.1080/00365590600830862 PMID: 17130101
9. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJ, et al. (1997) The International Continence
Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms. J Urol 157:
885–889. PMID: 9072592
10. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, et al. (2009) Tolterodine treatment improves
storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 56:
534–541. doi: 10.1016/j.eururo.2008.11.026 PMID: 19070418
11. Chung SD, Chang HC, Chiu B, Liao CH, Kuo HC (2011) The efficacy of additive tolterodine extended
release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. Neu-
rourol Urodyn 30: 568–571. doi: 10.1002/nau.20923 PMID: 21344494
12. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W (2009) Safety and tolerability of solifenacin
add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182: 2825–
2830. doi: 10.1016/j.juro.2009.08.023 PMID: 19837435
13. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, et al. (2006) Tolterodine and tamsu-
losin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized con-
trolled trial. JAMA 296: 2319–2328. doi: 10.1001/jama.296.19.2319 PMID: 17105794
14. Liu S, Chan L, Tse V (2014) Clinical outcome in male patients with detrusor overactivity with impaired
contractility. Int Neurourol J 18: 133–137. doi: 10.5213/inj.2014.18.3.133 PMID: 25279240
15. Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, et al. (2013) Clinical efficacy and safety of
imidafenacin as add-on treatment for persistent overactive bladder symptoms despite alpha-blocker
treatment in patients with BPH: the ADDITION study. Urology 82: 887–893. doi: 10.1016/j.urology.
2013.05.008 PMID: 23953605
16. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, et al. (2016) Long-term efficacy of a combi-
nation therapy with an anticholinergic agent and an alpha1-blocker for patients with benign prostatic
enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective,
comparative trial using a urodynamic study. Neurourol Urodyn.
17. Lee (2007) A Study on the Efficacy of Combination Therapy with Alpha-blockers and Anticholinergics in
the Lower Urinary Tract Symptoms Patients Accompanied with Overactive Bladder Symptoms.
18. Bae JH, Kim SO, Yoo ES, Moon KH, Kyung YS, et al. (2011) Efficacy and safety of low-dose propiverine
in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a
prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol 52: 274–278. doi:
10.4111/kju.2011.52.4.274 PMID: 21556215
19. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, et al. (2005) Combination treatment with propiverine
hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for
overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled
multicenter study. J Urol 174: 1334–1338. PMID: 16145414
20. Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY (2014) Effects of initial combined tamsulosin and solifenacin
therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia:
a prospective, randomized, multicenter study. Int Urol Nephrol 46: 523–529. doi: 10.1007/s11255-013-
0551-7 PMID: 24097273
21. Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, et al. (2011) Initial combined treatment with anticholiner-
gics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive blad-
der: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer
Prostatic Dis 14: 320–325. doi: 10.1038/pcan.2011.22 PMID: 21788967
22. Maruyama O, Kawachi Y, Hanazawa K, Koizumi K, Yamashita R, et al. (2006) Naftopidil monotherapy
vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with
benign prostatic hyperplasia: A prospective randomized controlled study. Int J Urol 13: 1280–1285. doi:
10.1111/j.1442-2042.2006.01538.x PMID: 17010005
23. Seo DH, Kam SC, Hyun JS (2011) Impact of lower urinary tract symptoms/benign prostatic hyperplasia
treatment with tamsulosin and solifenacin combination therapy on erectile function. Korean J Urol 52:
49–54. doi: 10.4111/kju.2011.52.1.49 PMID: 21344031
24. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, et al. (2013) Combination therapy with
solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract
Initial Combination Treatment of Alpha Blocker and Anticholinergics
PLOS ONE | DOI:10.1371/journal.pone.0169248 January 10, 2017 17 / 18
symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol
64: 1003–1012. doi: 10.1016/j.eururo.2013.07.034 PMID: 23932438
25. Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, et al. (2013) Efficacy and safety of solifenacin
plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a
phase 2, dose-finding study (SATURN). Eur Urol 64: 398–407. doi: 10.1016/j.eururo.2013.03.031
PMID: 23537687
26. Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, et al. (2009) Naftopidil and propiverine
hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyper-
plasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol
Nephrol 43: 307–314. doi: 10.1080/00365590902836740 PMID: 19396723
27. Dmochowski R (2006) Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evi-
dence? Curr Urol Rep 7: 462–467. PMID: 17052442
28. Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyper-
plasia. J Urol 173: 1256–1261. doi: 10.1097/01.ju.0000155709.37840.fe PMID: 15758764
29. Tehranchi A, Rezaei Y, Shojaee R (2014) Tolterodine to relieve urinary symptoms following transure-
thral resection of the prostate: a double-blind placebo-controlled randomized clinical trial. Korean J Urol
55: 260–264. doi: 10.4111/kju.2014.55.4.260 PMID: 24741415
30. Liao CH, Kuo HC (2015) How to choose first-line treatment for men with predominant storage lower uri-
nary tract symptoms: a prospective randomised comparative study. Int J Clin Pract 69: 124–130. doi:
10.1111/ijcp.12488 PMID: 25495719
31. Lee KW, Hur KJ, Kim SH, Cho SY, Bae SR, et al. (2016) Initial Use of High-Dose Anticholinergics Com-
bined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospec-
tive, Randomized Preliminary Study. Low Urin Tract Symptoms.
32. Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, et al. (2015) Long-term safety and efficacy of sin-
gle-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with stor-
age and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II
open-label extension. Eur Urol 67: 262–270. doi: 10.1016/j.eururo.2014.07.013 PMID: 25070148
33. Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the
treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004; discus-
sion 1004. doi: 10.1016/S0022-5347(05)00483-0 PMID: 16469601
34. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract
symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273–2275 discussion 2275–2276.
doi: 10.1097/01.ju.0000181823.33224.a0 PMID: 16280803
35. Andersson KE (2010) Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 29: 97–106.
doi: 10.1002/nau.20784 PMID: 20025035
36. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, et al. (2009) Impact of overactive bladder on work
productivity in the United States: results from EpiLUTS. Am J Manag Care 15: S98–S107. PMID:
19355804
37. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al. (2003) Prevalence and burden
of overactive bladder in the United States. World J Urol 20: 327–336. PMID: 12811491
38. Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, et al. (2013) Solifenacin plus tamsulosin com-
bination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a random-
ized controlled trial. Eur Urol 63: 158–165. doi: 10.1016/j.eururo.2012.07.003 PMID: 22831853
39. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188. PMID:
3802833
40. Nazir J, Heemstra L, van Engen A, Hakimi Z, Ivanescu C (2015) Cost-effectiveness of a fixed-dose
combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with
lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urol 15: 41. doi: 10.
1186/s12894-015-0031-8 PMID: 25956727
Initial Combination Treatment of Alpha Blocker and Anticholinergics
PLOS ONE | DOI:10.1371/journal.pone.0169248 January 10, 2017 18 / 18
